Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
NT-125 is discontinued, while two key Datroway readouts are delayed.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
AbbVie follows Gilead in throwing Xilio a lifeline.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.